Non-Hodgkin Lymphoma in Children and Adolescents: Progress Through Effective Collaboration, Current Knowledge, and Challenges Ahead
Year: 2015
Type: review
Abstract: Non-Hodgkin lymphoma is the fourth most common malignancy in children, has an even higher incidence in adolescents, and is primarily represented by only a few histologic subtypes. Dramatic progress has been achieved, with survival rates exceeding 80%, in large part because of a better understanding of the biology of the different subtypes and national and international collaborations. Most patients with Burkitt lymphoma and diffuse large B-cell lymphoma are cured with short intensive pulse chemotherapy containing cyclophosphamide, cytarabine, and high-dose methotrexate. The benefit of the addition of rituximab has not been established except in the case of primary mediastinal B-cell lymphoma. Lymphoblastic lymphoma is treated with intensive, semi-continuous, longer leukemia-derived protocols. Relapses in B-cell and lymphoblastic lymphomas are rare and infrequently curable, even with intensive approaches. Event-free survival rates of approximately 75% have been achieved in anaplastic large-cell lymphomas with various regimens that generally include a short intensive B-like regimen. Immunity seems to play an important role in prognosis and needs further exploration to determine its therapeutic application. ALK inhibitor therapeutic approaches are currently under investigation. For all pediatric lymphomas, the intensity of induction/consolidation therapy correlates with acute toxicities, but because of low cumulative doses of anthracyclines and alkylating agents, minimal or no long-term toxicity is expected. Challenges that remain include defining the value of prognostic factors, such as early response on positron emission tomography/computed tomography and minimal disseminated and residual disease, using new biologic technologies to improve risk stratification, and developing innovative therapies, both in the first-line setting and for relapse.
Source: Journal of Clinical Oncology
Authors: Véronique Minard-Colin, Laurence Brugières, Alfred Reiter, Mitchell S. Cairo, Thomas G. Gross, Wilhelm Woessmann, Birgit Burkhardt, John T. Sandlund, Denise Williams, Marta Pillon, Keizo Horibe, Anne Auperin, Marie-Cécile Le Deley, Martin Zimmerman, Sherrie L. Perkins, Martine Raphael, Laurence Lamant, Wolfram Klapper, Lara Mussolin, Hélène A. Poirel, Elizabeth Macintyre, Christine Damm-Welk, Angelo Rosolen, Catherine Patte
Institutions: Université Paris-Sud, F. Hoffmann-La Roche AG, Novartis (Switzerland), Hôpital Necker-Enfants Malades, Centre National de la Recherche Scientifique, Institut Gustave Roussy, Institut Necker Enfants Malades, Sorbonne Paris Cité, Assistance Publique – Hôpitaux de Paris, Roche (France), Merck Serono S.A. (Switzerland), Université Paris Descartes, Aspects métaboliques et systémiques de l'oncogénèse pour de nouvelles approches thérapeutiques, EUSA Pharma (United Kingdom)
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: green
Funders: Biogen, Institut Necker-Enfants Malades, University of Cambridge, Christian-Albrechts-Universität zu Kiel, Cambridge University Hospitals, Università degli Studi di Padova, Novo Nordisk, Centre National de la Recherche Scientifique, Université Paris Descartes, Institut Gustave-Roussy, Assistance publique-Hôpitaux de Paris, Health Science Center, University of Tennessee, National Cancer Institute, Cliniques Universitaires Saint-Luc
OpenAlex ID: W2162244898
